Search Results

Clinical Update Presented on Humacyte’s Investigational Human Acellular Vessel for Treatment of Vascular Trauma

September 9, 2022—Humacyte, Inc. announced the presentation of a clinical update on the company’s human acellular vessel (HAV) for treatment of vascular trauma.

SVS Announces New Collection of JVS Articles on Impact of COVID-19 in Treating Vascular Disease

May 6, 2020—The Society for Vascular Surgery (SVS) announced that a compilation of fast-tracked articles designed to proactively provide solutions to deliver the best care in the current COVID-19 environment has been published and organized as the COVID-19 Collection in the Journal of Vascular Surgery (JVS).

Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel for Vascular Trauma Repair

July 26, 2023—Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues, announced the completion of enrollment of V005, its phase 2/3 vascular trauma trial.

Ukrainian Surgeons Present Experience With Humacyte’s Human Acellular Vessel to Treat Wartime Vascular Trauma

September 23, 2022—Humacyte, Inc. announced that surgeons from Ukraine presented findings on the use of the company’s human acellular vessel (HAV) for the treatment of vascular trauma in the ongoing Russian-Ukrainian war.